Multitude Therapeutics is a clinical stage biopharmaceutical company established in 2019 to leverage its unparalleled target and antibody discovery arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) , combined with a proprietary ADC platform (T1000), to develop novel therapeutics for cancer treatment. The powerful synergy derived from combining MabArrayTM and T1000 enables Multitude to build an atlas of ADCs that has the potential to treat malignancies with high unmet medical needs. Multitude’s pipeline includes both first-in-class and best-in-class antibody-drug conjugates (ADCs) for solid and hematological tumors.
3698 Haven Avenue, Suite A
Redwood City, CA 94063, USA
JLABS @ Shanghai, 6th Floor, Building 1, South Building, Jinchuang Building, No. 4560 Jinke Road, Shanghai
& Unit 10, No. 159 Tianzhou Road, Xuhui District, Shanghai 200235